Effects Analysis Of BNP Expression In Blood Plasma On COPD

Background Chronic obstructive pulmonary disease(COPD) is a persistent airflow limitation for the characteristics of chronic bronchitis or emphysema, the airflow limitation is developing, that is not fully reversible and can be further developed into respiratory failure or pulmonary heart disease, the incidence and exogenous harmful substances and abnormal airway inflammatory reaction, morbidity and mortality is high, to the patient’s body and mind were made hurt growth.The clinical manifestations of COPD were improved, but the pulmonary function was not improved obviously, and the pulmonary hypertension(PH) was gradually developed. Brain natriuretic peptide is secreted by heart, which can promote urination, discharge sodium, blood vessels, and blood pressure. Many studies have found that the plasma brain natriuretic peptide and high sensitive C reactive protein(hs CRP) and arterial oxygen partial pressure(Pa O2), this study by on patients with chronic obstructive pulmonary disease(COPD) plasma brain natriuretic peptide(BNP) levels were detected, provide the practical basis for the treatment and prevention of COPD patients in clinic, provide good clinical guidance for the prognosis.Objective To investigate the utility of brain natriuretic peptide(BNP)for prognostication of COPD, plasma BNP was measured in patients with COPD without symptoms or physical findings of PH or cor pulmonale.Method Plasma BNP was measured in 60 patients with COPD, 10 asthmatics, and 30 healthy subjects. Echocardiography, arterial blood gas analysis, and spirometry were also performed. Mortality and exacerbation were compared between COPD patients with high and low plasma BNP levels over a 3-year follow-up period.Results Plasma BNP(mean ± SEM, pg/mL) in COPD patients(41.0±6.6) was significantly higher than in normal subjects(14.8±2.7)and asthmatics(17.4±4.5)(p<0.0001 and p<0.05, respectively). The period until initial COPD exacerbation in subjects with a high plasma BNP level was significantly shorter(p<0.05). Plasma BNP level during exacerbations(79.9±16.2) was also significantly higher than during stable disease(41.2±8.7)(p=0.004).Conclusion We suggest that plasma BNP is a non-invasive biomarker that can be used as a screening parameter for latent PH and left ventricular dysfunction, and also as a predictor of exacerbation in stable COPD.